Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia

MLA

Ferran Nadeu, et al. “Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia.” Blood, vol. 126, Dec. 2015, p. 4138. EBSCOhost, https://doi.org/10.1182/blood.v126.23.4138.4138.

APA

Ferran Nadeu, Julio Delgado, Cristina Royo, Tycho Bauman, Tatjana Stankovic, Magda Pinyol, Pedro Jares, Alba Navarro, David Martín-García, Sílvia Beà, Itziar Salaverria, Ceri Oldreive, Marta Aymerich, Helena Suárez-Cisneros, Maria Rozman, Neus Villamor, Dolors Colomer, Armando López-Guillermo, Marcos González, … Elías Campo. (2015). Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia. Blood, 126, 4138. https://doi.org/10.1182/blood.v126.23.4138.4138

Chicago

Ferran Nadeu, Julio Delgado, Cristina Royo, Tycho Bauman, Tatjana Stankovic, Magda Pinyol, Pedro Jares, et al. 2015. “Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia.” Blood 126 (December): 4138. doi:10.1182/blood.v126.23.4138.4138.